At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 101 enrolled
Drug / intervention
Fostamatinibdrug
Likely dose
Fostamatinib 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
In Brief
A Phase 2 clinical trial evaluating Fostamatinib for Diffuse Large B-Cell Lymphoma. Completed, enrolled 101 participants across 21 sites in 2 countries.
Detailed Summary
This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-Cell Lymphoma
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionOct 2013
TodayJul 2026
First PostedDec 26, 2011
Enrollment StartDec 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.5 years ago
Interventions
Fostamatinibdrug
Phase II Trial to evaluate the efficacy of 200mg fostamatinib